U.S. Orthopedic Prosthetics Market Size, Share & Forecast 2026–2032

ID: MR-11646 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Orthopedic Prosthetics Market
  • ✓Market Size 2024: USD 14.8 billion
  • ✓Market Size 2032: USD 23.6 billion
  • ✓CAGR: 6.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Outpatient Migration Reshapes Pricing: Ambulatory surgery centers now absorb a growing share of primary knee replacements since CMS added the procedure to its ASC list in 2020. Stryker and Zimmer Biomet now bundle robotic instruments with implants for ASC buyers.
FINDING 02
Robotics Will Not Expand Volume: Most investors assume robotic-assisted arthroplasty will expand total procedure volume. Stryker's Mako installed base confirms robots shift share toward platform-locked implants rather than adding patients, so entrants without a navigation ecosystem face exclusion.
ANALYST RECOMMENDATION

Analyst Recommendation — Enter Through ASC Partnerships: Medical device entrants should secure ASC group purchasing agreements with operators such as Surgery Partners and SCA Health before the end of 2026, because outpatient knee and hip volume is consolidating into fewer, price-sensitive buyers.

Orthopedic Prosthetics in the United States: Market Overview

The United States accounts for roughly 40% of global orthopedic prosthetics revenue, with the 2024 market valued at USD 14.8 billion across implantable joint reconstruction and external limb prosthetic devices. Hip and knee arthroplasty dominate the revenue base, and the country performs more primary total joint replacements than any other nation. Unlike the global market, which skews toward Asia Pacific volume growth, U.S. revenue reflects premium pricing, surgeon-driven implant selection, and reimbursement-led adoption. This concentration makes the U.S. the benchmark for pricing and product launches worldwide.

Market structure is consolidated at the implant level, with Stryker, Zimmer Biomet, and DePuy Synthes controlling most hip and knee revenue. Limb prosthetics follow a different model, with fragmented clinical fitting delivered through independent patient-care clinics and Hanger's national network of patient-care centers. Ottobock also holds a significant position in componentry. Distribution runs through direct sales representatives, hospital value analysis committees, and group purchasing organization contracts, so entry requires clinical evidence and surgeon adoption rather than price alone.

Growth Drivers in U.S. Orthopedic Prosthetics

Demographic demand is the strongest driver. Americans aged 65 and older numbered about 61 million in 2024 according to the U.S. Census Bureau, and this cohort generates most primary hip and knee replacements. Adult obesity prevalence above 40%, as reported by the CDC, accelerates osteoarthritis onset and pushes surgeons toward earlier joint intervention, particularly in the South Census Region. Younger patients are therefore entering arthroplasty pathways a decade earlier than prior generations.

Site-of-care policy is the second driver. CMS's 2020 addition of total knee arthroplasty to the ambulatory surgery center covered procedures list opened a lower-cost outpatient channel for elective cases. Medicare Advantage enrollment exceeding 32 million in 2024 has encouraged plans to steer patients toward lower-cost settings. Veterans Affairs prosthetics procurement through the VA Prosthetic and Sensory Aids Service adds sustained, federally funded demand for limb devices and componentry.

Market Restraints and Entry Barriers

FDA premarket clearance is the first gate. Most hip and knee implants reach market through the 510(k) pathway, while novel fixation or bearing designs require premarket approval under 21 CFR Part 814, with review timelines that routinely exceed twelve months. The Quality Management System Regulation under 21 CFR Part 820, aligned with ISO 13485 and effective February 2, 2026, adds audit and documentation costs for new manufacturing sites.

Incumbent contracting and reimbursement pressure form the second barrier. Hospitals negotiate through group purchasing organizations such as Vizient and Premier, and value analysis committees require outcomes data before approving a new implant system. CMS's Comprehensive Care for Joint Replacement model ties hospital payment to episode costs, pressuring implant prices. The Anti-Kickback Statute and Physician Payments Sunshine Act reporting restrict surgeon engagement, adding compliance overhead for new entrants.

Market Opportunities in U.S. Orthopedic Prosthetics

The fastest near-term opportunity is outpatient joint replacement. Ambulatory surgery center primary arthroplasty volume is growing faster than hospital volume, and an estimated USD 1.2 billion of annual knee and hip implant spend is expected to shift to ambulatory settings by 2028. Entrants with lower-cost, ASC-specific instrument sets and streamlined inventory models can capture share from incumbents built around hospital contracts.

Shoulder arthroplasty and limb prosthetics offer the second opportunity. Reverse total shoulder arthroplasty is among the fastest-growing procedures in the U.S., with annual volumes approaching 100,000 and rising suitability for ambulatory settings. In limb prosthetics, microprocessor knees and steady VA-funded procurement create a durable addressable base for componentry suppliers and digital fitting software.

Market at a Glance

MetricDetail
Market Size 2024USD 14.8 billion
Market Size 2032USD 23.6 billion
Growth Rate (CAGR)6.0%
Most Critical Decision FactorReimbursement alignment with ASC and bundled payment models
Largest RegionSouth Census Region
Competitive StructureConsolidated at implant level; fragmented in limb prosthetics

Leading Market Participants

  • Stryker
  • Zimmer Biomet
  • DePuy Synthes
  • Smith+Nephew
  • Enovis
  • Globus Medical
  • Exactech
  • Ottobock
  • Hanger
  • Embla Medical

Regulatory and Policy Environment

The Federal Food, Drug, and Cosmetic Act governs premarket review, administered by the FDA's Center for Devices and Radiological Health under MDUFA V through fiscal 2027. CMS administers Medicare payment through the Medicare Physician Fee Schedule for surgeon services and the Outpatient Prospective Payment System for hospital and ambulatory surgery center settings. The FDA Unique Device Identification rule requires GUDID labeling before commercial distribution.

Medicare's competitive bidding program for orthotic and prosthetic supplies, authorized under Section 1834(h) of the Social Security Act, sets contract prices for selected prosthetic devices. Original PMA application fees exceed USD 500,000 in fiscal 2025, and manufacturers must complete FDA registration and listing before commercial launch. The Anti-Kickback Statute and Stark Law constrain consulting and training arrangements with surgeons.

Long-Term Outlook for U.S. Orthopedic Prosthetics

By 2032 the market reaches an estimated USD 23.6 billion, growing at 6.0% annually. Procedure volume rises as baby boomers age, ASCs handle a larger share of knee and hip cases, and robotic platforms standardize implant selection. Revenue growth moderates as pricing pressure from bundled payments and competitive bidding offsets volume gains.

Consolidation and digital ecosystems define the 2032 market. Stryker, Zimmer Biomet, and DePuy Synthes will retain most hip and knee revenue, while mid-tier companies with specialty shoulder or extremity portfolios face acquisition pressure. Limb prosthetics shift toward connected microprocessor devices reimbursed under Medicare's prosthetic benefit, with Ottobock and Embla Medical competing on fitting analytics and outcomes data.

Frequently Asked Questions

Most hip and knee implants enter through the FDA 510(k) pathway, which requires demonstrating substantial equivalence to a legally marketed predicate device. Novel designs require premarket approval, and review timelines routinely exceed twelve months.
An estimated USD 1.2 billion of annual knee and hip implant spend is expected to shift to ambulatory settings by 2028. Entrants should prioritize ASC-specific instrument sets and streamlined inventory models.
Medicare covers medically necessary joint replacement procedures and prosthetic devices under Part B and the prosthetic benefit. Competitive bidding under Section 1834(h) sets contract prices for selected prosthetic supplies.
Vizient and Premier are the dominant group purchasing organizations negotiating hospital orthopedic implant contracts. Value analysis committees within each hospital must approve new implant systems before contract access.
The Quality Management System Regulation under 21 CFR Part 820 took effect on February 2, 2026, and aligns with ISO 13485. Manufacturers should complete gap assessments and audit readiness reviews well before scheduled FDA inspections.

Market Segmentation

By Product Type
  • Hip Prostheses
  • Knee Prostheses
  • Shoulder Prostheses
  • Ankle Prostheses
  • Upper and Lower Limb Prostheses
By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Orthotic and Prosthetic Clinics
  • Veterans Affairs Facilities
  • Specialty Orthopedic Clinics

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Orthopedic Prosthetics - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Hip Prostheses
4.2 Knee Prostheses
4.3 Shoulder Prostheses
4.4 Upper and Lower Limb Prostheses
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgery Centers
5.3 Orthotic and Prosthetic Clinics
5.4 Veterans Affairs Facilities
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Stryker
6.2.2 Zimmer Biomet
6.2.3 DePuy Synthes
6.2.4 Smith+Nephew
6.2.5 Enovis
6.2.6 Globus Medical
6.2.7 Exactech
6.2.8 Ottobock
6.2.9 Hanger
6.2.10 Embla Medical
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.